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Non-steroidal anti-inflammatory drugs (NSAIDs) have been demonstrated to have significant
cardiovascular and gastrointestinal toxicity; high dose of intake and concomitant use of multiple
compounds or corticosteroids are factors that increase the risk of NSAID toxicity. In this paper we
described our experience on NSAIDs misuse (both prescribing and OTC formulations), particularly
relevant in the setting of rheumatoid arthritis (39.5% of patients) and osteoarthritis (47% of patients).
We also evaluated causes underlying NSAIDs misuse (e.g, not satisfactory pain control, other painful
conditions, etc).
Non-steroidal-anti-inflammatory drugs (NSAIDs)
are commonly used for the treatment of chronic
diseases such as osteoarthritis (OA) and rheumatoid
arthritis (RA). These drugs have been demonstrated
to have significant cardiovascular (l, 2) and
gastrointestinal toxicity (3), in particular with high
dose intake or concomitant use ofmultiple compounds
(4) or corticosteroids (5). NSAIDs are commercially
available either as prescription-drug or over-the-
counter (OTC) medications. OTC formulations
contain lower dosages of the active principle as
compared to the corresponding prescription drug,
however, this does necessarily correlate with safer
patient outcome (6). From January 2012 to September
2012, a convenience sample of consecutive RA and
OA patients being followed-up in our outpatient-clinic
and for whom we had previously prescribed NSAID
were evaluated for NSAID patterns of consumption.
Per clinic protocol, all patients are informed of the
safety risks and precautions related to NSAID use.
Five hundred forty-six RA and 508 OA were assessed.
In all cases the NSAID prescribed in our clinic was
taken correctly, according to our indications. In the 2
months preceding the visit, 216 RA patients (39.5%)
concurrently took additional NSAIDs (over-users)
and 147 (27%) were simultaneously on chronic
corticosteroid treatment. Nimesulide (N= 90; 16%),
acetyl-salicylic-acid (N=57; 10%) and OTC ibuprofen
or diclofenac (N=105; 19%) were the most frequently
associated NSAIDs. Incomplete pain control (N=105;
19%), headache (N=111; 20%), fever (N=51; 9%)
and dental pain (N=24; 4%) were the predominant
reasons for additional NSAID treatment as prescribed
by other physician or self-administration. Neither
gender (p=0.0834) nor mean age (p=0.2564) were
different between NSAID over-user and non-over-
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Table I. Characteristics ofpatients evaluated.
L. CAVAGNA ET AL.
Rheumatoid arthritis Osteoarthritis
Patients' number 546 508
NSAIDs non over-user 330 (60.51 ___ 268 (53)
~~ll~llg~.(yellrs):i: ...~.!>....~()~o"er=lI~~.~ .......
---"
~§:t:_Jl~____.. f------------ 68.2 ± 7 £ -_._---
Females/male non over-user 250/801\ 155/113 0
NSAIDs over-user (%)
.__}1.~..(32·~) _______ 240 (47)f---------------.
.~ea~ag~Jy~ll~~):i:..~!>o,,~~=lIs~E 65 ± 8 §
-----
67 ± 11 £
_._----
Females/males over-user 149/671\ 150/90 0
--~'-------'--'
NSAIDs over-user with concomitant 147 (27) 0(0)
corticosteroids (%)
Reasons for NSAIDs over-use
105 (19)
-
unsatisfactor pain disease control
------
104 (20)
headhache (%) 111 (20) 56 (11)
fever 51 (9) 56 (11)
---d~~tai'p~i~'(o/0--------------------'-'-'-'
.-
24 (4.5) 48 (9)
other reasons" (%) 0(0) 10 (2)
more than 1 reason (%) 57 (10) 48 (9)
Associated NSAIDs
nimesulide ('XJ)
_.__.,_.,-,,---
-
..._____90 (1§2._.__
---
72 (14)
diclofenac (%) I.?_(?L_.. __ 8 (2)
----
piroxicam (%)
........_M.. ··_.. •.. ·_.. ···_.··~"· .. _ .... H_.. ""~' ... _H.. "~'.....__......_.
18 (3) 4 (I)
-------COXiB~-(%)---·--·· 6 (1)
.........
__________...J2.(3L_.____________
a(;~tyl=~~ly(;ili(;a(;i~('XJ2 57 (10) 108.<21)
.1-----_..
other prescribing NSAlDs (%) 6 (I) 0(0)
t~t~i··OTC··(%)·······································..........................................
105 (19)
._--". __..
80 (16)
......
. O!c.::i~llP~()feI1(ro) '---81 (15)-- _______60""(12L________.
OTe diclofenac (%) 24 (4) 20 (4)
* other reasons: post-traumatic pain, menstrual pain.fatigue. 1\ p=O.0834, 0 p=O.3184, § p=O.2564, £ p=O.1367
user RA patients. In the same period, 240 OA patients
(47%) took additional NSAIDs as prescribed by
other physicians or self-administration. Nimesulide
(N=72; 14%), acetyl-salycilic-acid (N= 108; 21%)
and OTe ibuprofen or diclofenac (80 patients; 16%)
were the mainly associated NSAIDs. Incomplete
pain control (104 patients; 20%), headache (56
patients; 11%), fever (56 patients; 11 %) and dental
pain (48 patients; 9%) were the main reasons for
additional NSAID use. Sex (p=O.3184) and mean
age (p=0.1367), were not different between NSAID
over-user and non-over-user OA patients. Table
I characterized differences between RA and OA
patients. Overall analysis reveals: a) NSAID overuse
is common in both RA and OA; b) it involves both
prescription and OTe drugs; and c) very importantly,
conditions other than disease-related pain may lead
to additional NSAID consumption as the result of
physician prescription or self-medications. These
findings indicate that physicians do not always take
into account the pharmaceutical background of
patients and patients are not completely aware of
risks associated with NSAID use, despite having been
previously informed, or perhaps are not familiar with
other medications in the family ofNSAIDs. Based on
these patterns of misuse revealed by this study and
others (7), clinicians must enhance their own habits
of medication reconciliation in regard to multiple
NSAIDs and concomitant glucocorticoid use as well
as their approach to patient education in order to
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emphasize safe NSAID use and hopefully reduce the
risk ofNSAID-re1ated side-effects.
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